[1] Bray, F, Ferlay, J, Soerjomataram, I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Guggenheim, D E, Shah, M A. Gastric cancer epidemiology and risk factors [J]. J Surg Oncol, 2013, 107(3): 230-6.
[3] Zhang, C H, He, Y L, Schwarz, R E,et al. Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes [J]. Chinese medical journal, 2014, 127(3): 435-41.
[4] Chen, W, Zheng, R, Baade, P D,et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-32.
[5] Kim, H S, Yi, S Y, Jun, H J,et al. Clinical outcome of gastric cancer patients with bone marrow metastases [J]. Oncology, 2007, 73(3-4): 192-7.
[6] Zhao, B, Zhang, J, Zhang, J,et al. The Impact of Preoperative Underweight Status on Postoperative Complication and Survival Outcome of Gastric Cancer Patients: A Systematic Review and Meta-analysis [J]. Nutr Cancer, 2018, 70(8): 1254-63.
[7] Song, Z, Wu, Y, Yang, J,et al. Progress in the treatment of advanced gastric cancer [J]. Tumour Biol, 2017, 39(7): 1010428317714626.
[8] Kodera, Y, Sasako, M, Yamamoto, S,et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer [J]. Br J Surg, 2005, 92(9): 1103-9.
[9] Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines. 5th ed.Tokyo: Kanehara Publishing Co., Ltd.;2018.
[10] Takashima, S, Kosaka, T. Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer [J]. Surg Today, 2005, 35(6): 425-31.
[11] Isozaki, H, Okajima, K, Fujii, K,et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer [J]. Hepato-gastroenterology, 1999, 46(25): 549-54.
[12] Sano, T, Sasako, M, Yamamoto, S,et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501 [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, 22(14): 2767-73.
[13] Yonemura, Y, Wu, C C, Fukushima, N,et al. Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy [J]. Hepato-gastroenterology, 2007, 54(74): 634-8.
[14] Shimoyama, S, Mafune, K, Kaminishi, M. Safety of a paraaortic node dissection for selected advanced gastric cancer patients [J]. Hepato-gastroenterology, 2005, 52(65): 1631-5.
[15] Fujiwara, Y, Omori, T, Demura, K,et al. A Multidisciplinary Approach for Advanced Gastric Cancer with Paraaortic Lymph Node Metastasis [J]. Anticancer research, 2015, 35(12): 6739-45.
[16] Oyama, K, Fushida, S, Kinoshita, J,et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes [J]. Journal of Surgical Oncology, 2012, 105(6): 535-41.
[17] Takeda, J, Koufuji, K, Kodama, I,et al. Para-aortic lymph node dissection for the treatment of advanced gastric cancer [J]. The Kurume medical journal, 1993, 40(3): 101-6.
[18] Hu, J K, Yang, K, Zhang, B,et al. D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery [J]. Surgery today, 2009, 39(3): 207‐13.
[19] Yonemura, Y, Wu, C C, Fukushima, N,et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer [J]. Int J Clin Oncol, 2008, 13(2): 132-7.
[20] Kulig, J, Popiela, T, Kolodziejczyk, P,et al. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial [J]. American journal of surgery, 2007, 193(1): 10-5.
[21] Bencivenga, M, Verlato, G, Giacopuzzi, S,et al. Survival benefit of superextended (D3) lymphadenectomy in subgroups of patients with advanced gastric cancer [J]. European Journal of Surgical Oncology, 2014, 40(11): S36.
[22] Morita, S, Fukagawa, T, Fujiwara, H,et al. The clinical significance of para-aortic nodal dissection for advanced gastric cancer [J]. European Journal of Surgical Oncology, 2016, 42(9): 1448-54.
[23] Moher, D, Liberati, A, Tetzlaff, J,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [J]. Int J Surg, 2010, 8(5): 336-41.
[24] Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses [J]. Eur J Epidemiol, 2010, 25(9): 603-5.
[25] DerSimonian, R, Laird, N. Meta-analysis in clinical trials [J]. Control Clin Trials, 1986, 7(3): 177-88.
[26] Higgins, J P, Thompson, S G, Deeks, J J,et al. Measuring inconsistency in meta-analyses [J]. BMJ, 2003, 327(7414): 557-60.
[27] Palma Perez, S, Delgado Rodriguez, M. [Practical considerations on detection of publication bias] [J]. Gac Sanit, 2006, 20 Suppl 3(10-6.
[28] Sasako, M, Sano, T, Yamamoto, S,et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer [J]. New England Journal of Medicine, 2008, 359(5): 453-62.
[29] Zhang, Y, Tian, S. Does D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decades [J]. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2013, 102(4): 251-7.
[30] Zhan, W H, He, Y L, Zheng, Z Q,et al. Effectiveness of para-aortic lymph node dissection for advanced gastric cancer [J]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2003, 41(5): 375-8.
[31] Kunisaki, C, Akiyama, H, Nomura, M,et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study [J]. Ann Surg Oncol, 2006, 13(5): 659-67.
[32] McCulloch, P. The role of surgery in patients with advanced gastric cancer [J]. Best Pract Res Clin Gastroenterol, 2006, 20(4): 767-87.
[33] Japanese Gastric Cancer, A. Japanese Classification of Gastric Carcinoma - 2nd English Edition [J]. Gastric Cancer, 1998, 1(1): 10-24.
[34] Japanese Gastric Cancer, A. Japanese gastric cancer treatment guidelines 2010 (ver. 3) [J]. Gastric Cancer, 2011, 14(2): 113-23.
[35] Sano, T, Aiko, T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points [J]. Gastric Cancer, 2011, 14(2): 97-100.
[36] Wu, C W, Hsiung, C A, Lo, S S,et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial [J]. The Lancet Oncology, 2006, 7(4): 309-15.
[37] Pacelli, F, Doglietto, G B, Bellantone, R,et al. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients [J]. Br J Surg, 1993, 80(9): 1153-6.
[38] Volpe, C M, Koo, J, Miloro, S M,et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma [J]. J Am Coll Surg, 1995, 181(1): 56-64.
[39] Harrison, L E, Karpeh, M S, Brennan, M F. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer [J]. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 1998, 2(2): 126-31.
[40] Onate-Ocana, L F, Aiello-Crocifoglio, V, Mondragon-Sanchez, R,et al. Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma [J]. Ann Surg Oncol, 2000, 7(3): 210-7.
[41] Kasakura, Y, Mochizuki, F, Wakabayashi, K,et al. An evaluation of the effectiveness of extended lymph node dissection in patients with gastric cancer: a retrospective study of 1403 cases at a single institution [J]. J Surg Res, 2002, 103(2): 252-9.
[42] Edwards, P, Blackshaw, G R, Lewis, W G,et al. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma [J]. Br J Cancer, 2004, 90(10): 1888-92.
[43] Mogal, H, Fields, R, Maithel, S K,et al. In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3? [J]. Ann Surg Oncol, 2019,
[44] Douridas, G N, Pierrakakis, S K. Is There Any Role for D3 Lymphadenectomy in Gastric Cancer? [J]. Frontiers in surgery, 2018, 5(27.
[45] Roviello, F, Pedrazzani, C, Marrelli, D,et al. Super-extended (D3) lymphadenectomy in advanced gastric cancer [J]. Eur J Surg Oncol, 2010, 36(5): 439-46.
[46] Maeta, M, Yamashiro, H, Saito, H,et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy [J]. Surgery, 1999, 125(3): 325-31.
[47] de Manzoni, G, Di Leo, A, Roviello, F,et al. Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer [J]. Ann Surg Oncol, 2011, 18(8): 2273-80.
[48] Smith, D D, Schwarz, R R, Schwarz, R E. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, 23(28): 7114-24.
[49] Gholami, S, Janson, L, Worhunsky, D J,et al. Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative [J]. J Am Coll Surg, 2015, 221(2): 291-9.
[50] Yoshikawa, T, Sasako, M, Sano, T,et al. Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized controlled trial [J]. British journal of surgery, 2006, 93(12): 1526‐9.
[51] Park, I H, Kim, S Y, Kim, Y W,et al. Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement [J]. Cancer Chemother Pharmacol, 2011, 67(1): 127-36.
[52] Tokunaga, M, Ohyama, S, Hiki, N,et al. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? [J]. Ann Surg Oncol, 2010, 17(8): 2031-6.
[53] Fushida, S, Oyama, K, Kinoshita, J,et al. Significance of para-aortic lymph node dissection for advanced gastric cancer patients following DCS therapy [J]. Annals of Oncology, 2016, 27(ix71-ix2.
[54] Lee, J H, Ryu, K W, Lee, J H,et al. Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery [J]. Ann Surg Oncol, 2006, 13(9): 1175-81.